All In Biotech

Drug Trial Radar · NCT03316729

DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)

Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects With Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)

Last checked: Nov 19, 2026Latest source record: Dec 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jan 2018

Primary completion

Feb 2020

Study completion Feb 2020

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Oct 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate safety and initial effectiveness of DS-9231 when taken together with current standard of care. Evaluation will be done with low, medium and then high doses of DS-9231 versus placebo, in participants with medium-risk acute pulmonary embolism.

Conditions

  • Pulmonary Embolism

Interventions

  • DS-9231Drug

    DS-9231 in saline solution for intravenous infusion

  • PlaceboDrug

    Placebo is matching saline solution for intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in total thrombus volumeTime frame: Baseline, 48-96 hours after study drug administration
  2. Percentage of participants with various gradations of decrease in total thrombus volumeTime frame: Baseline, 48-96 hours after study drug administration
  3. Number of participants with major or clinically relevant nonmajor bleedingTime frame: within 7 days after study drug administration
  4. Number of participants with adverse eventsTime frame: within 30 days after study drug administration

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.